Non - Alcoholic Steatohepatitis

A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects

Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis

Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia

Soluble Fibre Supplementation in NAFLD

Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatitis.

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

The Role of Immune Semaphorins in NAFLD

the Efficacy and Safety of Diosmin on Non-diabetic Patients With Non-alcoholic Steatohepatitis.

The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults

Bariatric Surgery Versus Non-alcoholic Steato-hepatitis

Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis

Omics-based Predictors of NAFLD/Potential NASH

Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

Coffee Consumption and NASH in the French Population.

Expanding Donor Pool for Live Donor Liver Transplantation: Utilization of Donors With NASH After Optimization